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Abstract
Prion diseases are transmissible spongiform encephalopathies in humans and animals, including scrapie in sheep, bovine
spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in deer, and Creutzfeldt-Jakob disease (CJD) in
humans. The hallmark of prion diseases is the conversion of the host-encoded prion protein (PrPC) to its pathological
isoform PrPSc, which is accompanied by PrP fibrillation. Transmission is not restricted within one species, but can also occur
between species. In some cases a species barrier can be observed that results in limited or unsuccessful transmission. The
mechanism behind interspecies transmissibility or species barriers is not completely understood. To analyse this process at a
molecular level, we previously established an in vitro fibrillation assay, in which recombinant PrP (recPrP) as substrate can be
specifically seeded by PrPSc as seed. Seeding with purified components, with no additional cellular components, is a direct
consequence of the ‘‘prion-protein-only’’ hypothesis. We therefore hypothesise, that the species barrier is based on the
interaction of PrPC and PrPSc. Whereas in our earlier studies, the interspecies transmission in animal systems was analysed,
the focus of this study lies on the transmission from animals to humans. We therefore combined seeds from species cattle,
sheep and deer (BSE, scrapie, CWD) with human recPrP. Homologous seeding served as a control. Our results are consistent
with epidemiology, other in vitro aggregation studies, and bioassays investigating the transmission between humans, cattle,
sheep, and deer. In contrast to CJD and BSE seeds, which show a seeding activity we can demonstrate a species barrier for
seeds from scrapie and CWD in vitro. We could show that the seeding activity and therewith the molecular interaction of PrP
as substrate and PrPSc as seed is sufficient to explain the phenomenon of species barriers. Therefore our data supports the
hypothesis that CWD is not transmissible to humans.
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Introduction
Prion diseases are transmissible spongiform encephalopathies
(TSE), which occur in mammals, including scrapie in sheep,
bovine spongiform encephalopathy (BSE) in cattle, chronic
wasting disease (CWD) in deer and Creutzfeldt-Jakob disease
(CJD) in humans. The infectious agent, referred to as prion, is
composed mainly, if not exclusively, of the pathological isoform of
the host-encoded prion protein (PrP). The key molecular event in
prion diseases is the misfolding and aggregation of the cellular
isoform of PrP, denoted as PrPC, into the pathological isoform,
PrPSc [1]. This conversion is accompanied by a shift from a-helical
dominated to b-sheet-rich secondary structure which results in
insolubility and aggregation. The aetiology of prion diseases can
be spontaneous, genetic or infectious. In analogy, CJD can occur
spontaneously (sCJD), as genetic form (fCJD) or as variant form
(vCJD), which was transmitted by BSE-afflicted cattle in the 1980s
[2].
Scrapie was first described several hundred years ago and
transmissibility among sheep could be shown in the 1930s [3].
Since the BSE epidemic it has become apparent that prions can be
transmitted from one species to another e.g. from sheep to cattle
[4]. The discovery of interspecies transmission became even more
alarming with the incidence of vCJD, which has been shown to be
caused by the consumption of BSE contaminated food [5].
Interestingly, there are transmission barriers between some
species leading to no or at least a much less effective transmission.
Scrapie, for instance, is known for almost three centuries and yet
no case of transmission from sheep to humans has been described.
In addition, experimental transmission studies in transgenic rodent
models have been found to result in prolonged incubation time
and an incomplete attack rate – a phenomenon which is referred
to as the species barrier [6]. A recent study reported, that the
species barrier has a tissue specificity, adding even more
complexity [7]. Beyond this, it is still uncertain if the species
barrier is a result of an ineffective route of infection, cellular
cofactors, incompatibility between pathogenic PrPSc and the host-
encoded PrPC or a combination thereof.
Several mechanisms have been proposed to describe the
conversion of PrPC to PrPSc [8]. One widely accepted is the
seeded polymerization model [9–12]. To analyse this conversion
process at a molecular level, we have previously developed an in
vitro assay which is able to generate PrP fibrils de novo [13,14].
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Recombinantly expressed PrP (recPrP) is suspended in physiolog-
ical sodium phosphate buffer and very low concentrations of
sodium dodecyl sulfate (SDS), establishing a well-defined pre-
amyloid state [11,15]. Based on this, we also established a seeded
fibrillation assay, which is suitable to analyse PrP fibrillation
mechanistically, as it is only consisting of recPrP and prion seeds,
derived from brain tissue precipitated by phosphotungstic acid
(NaPTA) [16,17]. No additional cellular extracts are needed.
In an earlier study, Caughey and colleagues studied the
conversion of cellular PrP from N2a cells by infectious brain
samples, applying close to stoichiometric ratios of PrPSc and PrPC
[18]. For heterologous systems a ‘‘relatively ineffective conversion
of human PrPC by PrPBSE’’ was shown. Further, ‘‘CWD
transmissions to humans would be as limited by PrP incompat-
ibility as transmission of BSE or scrapie to humans’’ [19].
In previous studies, we combined seeds and recPrP from
different species. We could show, that our assay perfectly matches
the known in vivo transmissibilities between sheep, cattle, mice and
hamster [20,21]. With our seeded fibrillation assay we could
model the interspecies transmission from sheep to cattle and from
sheep to Syrian hamster (SHa), while the species barrier between
sheep and mouse was confirmed.
In a similar seeding approach, but with different partially
denaturing incubation conditions, ‘‘promiscuous seeding’’ between
hamster seeds and mouse PrPC was observed [22].
In the present study, we extended the seeded fibrillation assay to
the cervid and human system to address public health concerns of




Genes coding the human PrP 90-231 (UniProtKB/Swiss-Prot:
P04156) and cervid recPrP 89-231 (UniProtKB/Swiss-Prot:
Q7JIQ1) were cloned from synthetic vectors (pMK; Mr. Gene)
into expression vector pET 16b and then electro transformed into
E. coli BL 21 Rosetta (DE3) pLysS cells (Merck/Novagen). Purified
plasmids of selected clones were sequenced (StarSEQ) for
sequence verification. An E.coli stock solution of each clone was
stored at –80uC. After sequencing, only stocks with verified
sequence have been used for further experiments.
Human recPrP 90–231 (huPrP) and cervid recPrP 89–231
(cerPrP) expression was induced by adding 1 mM Isopropyl-b-D-
thiogalactopyranosid (IPTG; Fermentas) to a 1 L E.coli culture
with a cell density of OD600 = 1.5. PrP expression was performed
at 30 uC and 200 rpm for 20 h. Cells were harvested by
centrifugation at 4,000 rcf (Beckman Coulter Allegra X15).
Purification
1 g E.coli cell pellet was suspended in 5 ml phosphate buffered
saline (PBS; 0.01 M phosphate; 0.138M NaCl; 0.027 M KCl,
[pH 7.4]),containing protease inhibitor (complete mini EDTA
free; Roche), 10 mg/ml DNAse I grade II and 20 mM MgCl2
(Sigma-Aldrich) at RT. Cells were lysed by application of a French
press (Constant Systems; One Shot Cell Disruptor) at 2.5 kbar, the
resulting lysate was pelleted. Pellets were suspended in 5 ml 8 M
guanidinium chloride (GndHCl; Sigma-Aldrich), 12.5 mM
TrisHCl [pH 8] (Sigma-Aldrich) and incubated over night at
4uC in an head-over-tail rotator. The resulting suspension was
centrifuged at 50,000 rcf and 10uC. The supernatant was used for
metal ion affinity chromatography (IMAC).
IMAC was performed on an A¨kta prime system (GE Healthcare
(Amersham bioscience) using 1 ml NiNTA columns (NM;
Protino). Equilibration/wash buffer was 6 M GndHCl, 0.1 M
NaPi (NaH2PO4/Na2HPO4; [pH 7.4]); 0.1 M TrisHCl 0.15 M
NaCl and 0.02 M Imidazole [pH 8]. Elution buffer equalled
equilibration buffer with NaCl and imidazole concentration raised
to 0.5 M.
Elution peak was incubated with 10 mM dithiothreitol (DTT;
Sigma-Aldrich) for 1 hour at RT. A buffer exchange was
performed (6 M GndHCl; 12.5 mM TrisHCl; [pH 8]) in
centricon filtration units (Centricon, Millipore, 10 kDa MWCO).
The protein solution was then incubated for 24 hours at RT with
10 mM oxidised glutathione (GSSG; Sigma-Aldrich) and 1 mM
reduced glutathione (GSH; Sigma-Aldrich). Buffer was exchanged
again to 6 M GndHCl and the protein was refolded by rapid
dilution with 10:1 1.1x Factor Xa cleavage buffer. At this point,
protein concentration was roughly estimated by absorption
spectrometry using calculated molar extinction coefficients. His
tag was removed by digestion with 0.1 U factor Xa (Merck/
Novagen) per mg PrP. After Cleavage at RT for 24 hours, final
purification by reversed phase high performance liquid chroma-
tography (rp-HPLC) followed.
Rp-HPLC was performed on a HPLC system (Knauer Well-
Chrom K-1001) with 50 ml Eurosil 300 C4 column. Running a
gradient of acetonitrile and ultrapure water at a flow rate of 5 ml/
min the recPrP was eluted at 40–42% acetonitrile. Eluted protein
was then lyophilised and dissolved in stock buffer containing
10 mM NaPi [pH 7.4] and 0.1% SDS. After estimation of protein
concentration by BCA-assay (Thermo Scientific; Pierce) and
absorption spectrometry protein stocks were stored at –80uC.
Circular Dichroism (CD) spectroscopy
CD measurements were carried out in a Jasco J-815 CD
spectropolarimeter at a fixed temperature of 20uC. Protein
samples were diluted to a final concentration of 18 mM. Prior to
CD measurements, 250 mM NaCl was added and the solution
was adjusted to SDS concentrations between 0.01% and 0.2%
SDS. CD spectra were recorded between 260 and 190 nm using a
step size of 0.5 nm and 10 accumulations. Buffer spectra have
been recorded with similar settings and subtracted afterwards.
Analytical ultracentrifugation
Ultracentrifugation was performed in an Optima XL-A
analytical ultracentrifuge (Beckman Coulter) with absorbance
optics using an An-50 Ti rotor with aluminium 2-channel
centerpiece cells. HuPrP at 2.5 and 5 mM concentration was
analysed after incubation for 5 days at 37uC and 650 rpm in
fibrillation buffer (10 mM NaPi [pH 7.4]; 250 mM NaCl; 0.02%
SDS) to reach pre-amyloid state. Sedimentation velocity centrifu-
gation was conducted at 40,000 rpm (128,794 rcf at 7.2 cm) and
20uC. Scans were recorded in intensity mode at 230 nm at 6 min
intervals with a radial resolution of 0.003 cm and transformed to
absorbance scans afterwards. For data evaluation a non-interact-
ing independent species model from the software package
Ultrascan 3 (www.ultrascan.uthscsa.edu) was applied using a vbar
of 0.7102 cm3/g based on the sequence of huPrP [23]. The fitting
procedure consisted of a 2-dimensional spectrum analysis followed
by a genetic algorithm and was finalised by Monte Carlo statistics
[24–26]. Reported s-values are corrected for water at 20uC.
Calculations were performed on the UltraScan LIMS cluster at
the Bioinformatics Core Facility at the University of Texas Health
Science Center at San Antonio. XSEDE resources were supported
by NSF Teragrid Grant #MCB070038 (to Borries Demeler).
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De novo SDS-based fibrillation assay
Analysis of kinetics of PrP fibrillation is based on protocols
published previously [14]. Samples have been measured in a
microtiterplate (MTP) in a fluorescence reader (TECAN;
M200Pro) at 37uC. Every 30 minutes, fluorescence emission was
measured at 482 nm (lex: 445 nm) averaging 25 single measure-
ments for every well and time point. Between measurements (max.
5 minutes), the MTP was agitated rigorously by linear shaking at
an amplitude of 2 mm (<600 rpm) for at least 25 minutes. 9 mM
PrP in NaPi containing 250 mM NaCl, 0.01–0.05% SDS and
5 mM Thioflavin T (ThT) at a final volume of 300 ml was
measured in black 96-U-well microtiterplate (Nunc) sealed with
adhesive foil (Thermo Scientific/Nunc, optical grade). Measure-
ments for the de novo SDS-based fibrillation assay were conducted
for at least three weeks.
TIRF microscopy of ThT stained huPrP fibrils
Total internal reflection fluorescence (TIRF) microscopy was
performed using a Leica AM TIRF MC equipped with a HCX PL
APO 10061.47 oil immersion objective (Leica microsystems).
Prior to TIRF analysis, cover slips (256660.17 mm; Menzel
Gla¨ser; Thermo Fisher Scientific) were cleaned with 2%
Hellmanex III for 15’ in an ultrasonic bath. After washing 10
times with in ultrapure water and once with absolute ethanol for
1’, slips were dried under a stream of nitrogen gas. For
immobilization of aggregates on a glass surface 5 ml of de novo
generated huPrP fibrils (from a monomer solution containing 9mM
huPrP) have been dried on a cover slip at RT. 10 ml of ThT
solution (10 mM) was added and fibrils were visualised in TIRF
mode (penetration depth 150 nm) with lex: 405 nm. ThT
fluorescence was detected by EM-CCD camera (Model 9100-2,
Hamamatsu) at an exposure time of 1 s. Images were post-
processed by adjusting contrast and brightness in open source
imaging software ImageJ (available at http://rsb.info.nih.gov/ij;
Wayne Rasband, National Institutes of Health, Bethesda, MD).
Transmission electron microscopy (TEM) of negative-
stained huPrP fibrils
5 ml of fibrillar recPrP (confirmed by ThT fluorescence) was
placed on a glow discharged grid and left to adsorb for 1 minute.
The sample was washed with 50 ml of 0.1 and 0.01 M ammonium
acetate and stained with 50 ml 2% ammonium molybdate. Dried
samples were analysed with a Tecnai F20 transmission electron
microscope at 80 kV.
PrPSc pre-purification by NaPTA precipitation
NaPTA-precipitation of PrPSc from brain tissue is a standard
procedure for the preparation of infectious prion samples. The
purification protocol is described in [20] and was performed
identical for each sample used within this work. 700 ml of 5%
brain homogenate (10% in case of sheep) in homogenisation buffer
(16 PBS; 4% Sarcosyl; proteinase inhibitor) was thawed for 15
minutes at 37uC and 650 rpm. Brief centrifugation in a table top
centrifuge at 2,000 rcf at 20uC. Addition of 500 ml 4% NaPTA
[pH 7.4] to 500 ml of the resulting supernatant. 60 minutes
incubation at 37uC and 650 rpm followed by 30 minutes of
centrifugation at 14,000 rcf at 20uC. Removal of supernatant and
addition of 200 ml 2% NaPTA [pH 7.4] and 2% N-lauroylsarco-
sine (sarcosyl) followed by a brief ultrasonification (50W; 5
seconds). This centrifugation step followed by removal of the
supernatant and ultrasonification in exchanged buffer is repeated
three times with 200 ml of 100 mM NaPi [pH 7.4] followed by
200 ml and finally 100 ml of 10 mM NaPi [pH 7.4]. The resulting
seed was used for the following seeded fibrillation assay.
Corresponding to the respective diseases NaPTA precipitate are
denoted as seed: CJD seed; BSE seed; scrapie seed and CWD seed.
Seeds from brain tissue of healthy animals are denoted as controls.
Samples of brain tissue were kindly provided by Oliver
Andreoletti, INRA ENVT (classical scrapie; Medulla), Martin
Groschup, Bundesforschungsanstalt fu¨r Viruskrankheiten der
Tiere (classical BSE, Medulla), Neil Cashman, Canadian Coop-
erative Wildlife Health Centre (CWD; White-tailed deer) and
Hans Kretzschmar, Institut fu¨r Neuropathologie und Prion-
forschung der LMU (sCJD)
Seeded SDS-based fibrillation assay
The seeded fibrillation assay is based on a previous protocol
[11,20] and was conducted as described in paragraph ‘‘De novo
SDS-based fibrillation assay’’ with the following exceptions: (i)
SDS concentration was fixed to 0.02% SDS, (ii). Time frame for
measurements was maximum seven days and (iii) a 50 ml seed
(prepared as described in paragraph ‘‘PrPSc purification by
NaPTA precipitation’’) was added.
Seeding activity was calculated by dividing the average of
relative fluorescence of samples with PrPSc positive seeds and
PrPSc negative seeds within 80–100 h (plateau phase). Homolo-
gous combinations of seed and substrate (e.g. CJD seed in huPrP)
always served as positive controls for heterologous seeding
experiments.
Statistical analysis of multiple seeding experiments
To test for statistical significant differences between seeding
experiments of human seeds in huPrP (intraspecies case) and
ovine, bovine or cervid seeds in huPrP (interspecies case) we
reproduced these experiments several times and calculated the
seeding activity for those combinations. Data is illustrated as
Tukey’s box plot. An ANOVA with additional Tukey’s range test
was performed with the log2 of each value (seeding activity of each
individual experiment), which is necessary to get normally
distributed values when analysing fluorescence data near zero.
Ethics Statement
The study was submitted to the ethics committee of the medical
faculty of the Heinrich-Heine-University of Du¨sseldorf (Ethik-
kommission an der Medizinischen Fakulta¨t der Heinrich-Heine-
Universita¨t Du¨sseldorf). The Ethics committee waived approval,
since there were no ethical concerns about this study. Human
brain samples were obtained from the Society for prion research
Germany (Gesellschaft zur Fo¨rderung der Prionforschung e.V. c/o
Zentrum fu¨r Neuropathologie & Prionforschung, Mu¨nchen).
Patients’ next to kin gave their written consent for autopsy. All
data were analysed anonymously. Bovine brain samples were
obtained from the national reference laboratory for BSE in
Germany (Bundesforschungsanstalt fu¨r Viruskrankheiten der
Tiere) Ovine brain samples were obtained from the National
Veterinary School of Toulouse (E´cole Nationale Ve´te´rinaire de
Toulouse). Cervid brain samples were obtained from the
Canadian Cooperative Wildlife Health Centre (Western College
of Veterinary Medicine; University of Saskatchewan).
Results
In order to analyse the molecular mechanism of fibrillation of
human recombinant PrP (huPrP) in our SDS based fibrillation
assay, we determined the particular concentrations of recPrP and
SDS, which trigger de novo fibrillation of PrP after several weeks. In
Molecular Basis of Prion Species Barrier
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contrast, fibrillation in the presence of seeds can be observed
within days or even hours, underlining the efficiency of seeding.
The conformation of PrP under conditions which enable
fibrillation is called pre-amyloid state [11]. The pre-amyloid state
of huPrP was characterised by biophysical methods including
circular dichroism (CD) spectroscopy and analytical ultracentrifu-
gation. De novo and seeded fibril formation was monitored by ThT
fluorescence and fibrils generated were visualised by ThT-stained
TIRF and electron microscopy. To analyse the species barrier
phenomenon a seeded fibrillation assay on the basis of huPrP was
established. NaPTA precipitates of brain tissue of different prion
infected species as seeds were combined with human recPrP as
substrate.
Pre-amyloid state of huPrP
CD spectroscopy has been applied to determine the secondary
structure of the pre-amyloid state of human recPrP 90-231
(huPrP). A concentration series of SDS ranging from 0.01–0.2%
was prepared containing 18 mM huPrP. In SDS concentrations
ranging from 0.04–0.2% a mixture of a-helical and random-coil
secondary structure was observed, as indicated by a pronounced
minimum at 208 nm. In SDS concentrations ranging from 0.02–
0.03%, the spectrum shifts towards a minimum at 220 nm with a
zero-crossing at higher wavelength, suggesting a b-sheet dominat-
ed secondary structure (Fig. 1 A).
Analytical ultracentrifugation in sedimentation velocity mode
was used to analyse the state of oligomerisation of the pre-amyloid
state of huPrP. Data analysis of the 5 mM huPrP sample revealed
two species. The most prominent species (,65%) has an s-value of
3.1560.01 S and a frictional ratio of 1.5. The quality of the fit was
confirmed by the low root mean square deviation (RMSD) value
of 0.00322 A230 (Fig. 1 B and C).
This species with a calculated molecular weight of
40.760.25 kDa is interpreted as a huPrP dimer. The huPrP
dimer has a calculated molecular weight of 32.6 kDa. Difference
in calculated molecular weight from sedimentation velocity
analysis is interpreted as the solvation of the protein and the
binding of SDS molecules to the protein complex.
A second species has an s-value of 0.18660.003 S and a
frictional ratio of 1. The corresponding molecular weight is far too
low to be interpreted as monomeric PrP.
It can be rather interpreted as an artefact arising from a non-
zero baseline, which might be caused most probably by SDS.
Lowering the protein concentration to 2.5 mM huPrP did
produce very similar results. A small species corresponding to the
non-zero baseline and one species at 3.060.02 S with
40.060.4 kDa based on a frictional ratio of 1.5 corresponds to
the dimeric huPrP (RMSD of 0.0034 A230). Again no species
corresponding to monomeric huPrP was detected.
De novo fibrillation of huPrP
To analyse de novo fibril formation of huPrP, samples containing
3 and 9 mM huPrP were incubated with 0.02–0.05% SDS for
three weeks at 37uC with constant agitation. Fibril formation was
monitored by Thioflavin T (ThT) fluorescence, which serves as an
specific indicator for the presence of amyloid fibrils.
Fibril formation depends both on SDS and huPrP concentra-
tion. Samples containing 9 mM huPrP and 0.02% SDS showed an
increase in ThT fluorescence within 400 hours (Fig. 2 A). Within
this time frame, all other combinations did not show increased
ThT fluorescence. The kinetics follow a sigmoid curve with a lag
phase of about 100 hours, reaching a plateau at about 250 hours
of incubation.
Morphology and size of huPrP aggregates were analysed by
TIRF and electron microscopy after ThT staining. ThT stained
huPrP aggregates with an estimated average length of about 1 to
5 mm were found. Aggregates of fibrillar character and also bigger
aggregates of highly ThT-stained protein are the most abundant
species visible (Fig. 2 B). Similar results were obtained by negative-
stain TEM of de novo huPrP fibrils. HuPrP aggregated into
prototypical amyloid fibrils with an estimated diameter between 15
to 20 nm (Fig. 2 C).
Figure 1. Pre-amyloid state of huPrP – CD spectroscopy and sedimentation velocity analysis of huPrP. CD spectra (A) of huPrP with
varying concentrations of SDS (0.02–0.2%) have been recorded directly after adapting the SDS buffer conditions. CD spectra show a shift from a-
random dominated towards b-sheet rich secondary structure with decreasing concentration of SDS. (B and C) A sedimentation velocity experiment
at 20uC and 40.000 rpm was performed to determine the state of oligomerisation of huPrP. Fig. 1 B shows the successive radial absorbance scans of
5 mM huPrP, which have been corrected for time and radially invariant noise. For clarity only every 3rd scan was plotted. Fig. 1 C shows the deviation
of measured data points from the fitted sedimentation boundary after the fitting procedure using Ultrascan 3. The absorption difference at 230 nm is
plotted in relation to the distance from the rotor axis. The RMSD of the fit was 0.00322 A230.
doi:10.1371/journal.pone.0072623.g001
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Seeded fibrillation of huPrP
CJD seeds and huPrP as substrate were analysed as an
intraspecies combination which serves as a positive control. While
brain samples of confirmed CJD victims are able to seed
fibrillation, age-matched controls of non-CJD samples did not
seed fibrillation (Fig. 3 A). The kinetics show an increase in ThT-
specific fluorescence after a lag phase of about 20 hours which is
about five times shorter than in the de novo fibrillation assay (Fig. 2
A). A concentration of 0.02% SDS was used in the seeding assay to
promote the formation of the pre-amyloid state. However, to
suppress de novo fibril formation, only 3 mM huPrP was used in the
seeded fibrillation assay.
De novo and seeded fibrillation of cerPrP
To analyse a species barrier between cervids and humans, fibril
formation of cerPrP was established in the de novo fibrillation assay
as described above. As shown for huPrP, a similar shift in
secondary structure within the SDS concentration series was also
found for cerPrP (Fig. 4 A). Also de novo fibril formation could be
shown for 9 mM cerPrP in 0.02% SDS (Fig. 4 B), the
corresponding CD spectra indicate a b-sheet rich secondary
structure. The seeding ability of CWD seeds and controls were
analysed in 3 mM cerPrP in 0.02% SDS. An increase of ThT
fluorescence within 40 to 60 hours was detected only in the sample
with CWD seeds (Fig. 4 C).
Fibrillation of huPrP seeded by animal seeds
We have established the huPrP fibrillation assay in order to test
whether fibrillation of huPrP can be seeded by scrapie, BSE or
CWD seeds. The combination of seed and substrate of one and the
same species always served as positive control. Seed prepared out
of non-infected brain tissue always served as negative control. The
corresponding studies using BSE and scrapie seeds in combination
with recPrP from cattle and sheep, respectively, were described
earlier [20,21]. In these studies, it could be shown that seeds from
BSE and scrapie are able to promote fibril formation of bovine or
ovine recPrP, respectively. Scrapie seeds were also able to seed the
fibril formation of bovPrP, representing a heterologous combina-
tion of seed an substrate. On the contrary, species barriers could
be shown for hamster seed in recombinant mouse PrP and BSE
seed in recombinant hamster PrP, i.e. no interspecies seeding
activity could be shown with these combinations.
In this study, BSE seeds and control seeds were combined with
huPrP as substrate, showing an increase in ThT fluorescence only
in samples containing BSE seed, whereas no increase was observed
for control seeds (Fig. 3 B). This seeding activity, shown in our in
vitro assay, matches the experimentally shown interspecies trans-
mission in vivo [5].
However, no seeding activity was observed, when scrapie prions
were used with huPrP as substrate. No increase in ThT
fluorescence was detectable for NaPTA preparations of scrapie-
positive or scrapie-negative tissue (Fig. 3 C).
Finally, we explored the question if CWD seeds are able to seed
fibril formation of huPrP. As shown above, huPrP can be
converted with CJD seeds (Fig. 3 A) and cerPrP with CWD seeds
(Fig. 4 C), respectively. In the heterologous combination no
increase in ThT fluorescence could be observed, neither in the
sample with CWD-seed, nor in the negative controls (Fig. 3 D).
Thus, CWD seeds are not able to promote huPrP fibrillation in
our in vitro assay. This result suggests, that the species barrier
between humans and cervids observed in vivo (see discussion)
results from the direct interaction of cervid prions and human
PrPC.
The quantification of seeding activity (for calculation see
materials and methods) of all combinations analysed, is summa-
rised as Tukey’s box plot (Fig. 5). Seeding activity in huPrP was
shown for CJD (N=7) and BSE (N= 8) seeds, whereas no seeding
Figure 2. De novo fibrillation of huPrP – ThT kinetics and TIRF
micrographs. De novo fibrillation is shown in (A), an amyloid specific
increase in ThT fluorescence is only observable at 0.02% SDS and 9 mM
huPrP. (B) De novo generated amyloid fibrils (plateau phase) have been
stained by ThT and visualised by TIRF microscopy. (C) Ultrastructure of
negative-stained de novo huPrP fibrils obtained by transmission
electron microscopy. Bar equals 100 nm.
doi:10.1371/journal.pone.0072623.g002
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activity could be observed for scrapie (N= 10) or CWD (N=8)
seeds.
To show if these results are significant, we analysed every
combination of seed in huPrP at least 7 times. Statistical
significance, tested by an ANOVA with Tukey’s Test, is given
for the comparison of data sets for species combination human/
sheep (p = 0.00026) as well as human/cervid (p = 0.00108).
Discussion
The molecular dissection of the conversion pathway from PrPC
to PrPSc is still enigmatic and a major focus in prion research. In
regard to the species barrier phenomenon the molecular
mechanism of the conversion is of particular interest, since the
barrier between some species is insurmountable whereas trans-
mission between others is rather effective. In several in vitro and in
vivo studies it was attempted to predict the species barrier between
two species by quantification of sequence variations [27]. In recent
years, the conformational selection model proposes that the
adaptation of two structures is more important than the two
sequences [6]. It is assumed that the species barrier is determined
by the degree of overlap of permissible structures of PrPSc between
host and donor species. So far, a prognosis of a particular species
barrier on the basis of sequence or structural variations could not
be achieved.
Several in vitro systems, which mimic characteristics of PrP
conversion, have been established to induce structural character-
istics reminiscent of PrPSc or to generate and propagate infectivity
[28–30], rather than to mimic the species barrier.
As mentioned above, intra- and interspecies conversion was
assayed by Caughey and colleagues, who converted cellular PrP
from N2a cells by infectious brain samples, applying close to
stoichiometric ratios of PrPSc and PrPC [18]. For homologous
combinations, a conversion efficiency of up to 25% was
demonstrated. For heterologous combination a ‘‘relatively inef-
fective conversion of human PrPC by PrPBSE’’ was shown.
Furthermore, ‘‘CWD transmissions to humans would be as limited
by PrP incompatibility as transmission of BSE or scrapie to
humans’’ [19]. The results of this earlier conversion system led to
claims on species barriers in terms of relative effectiveness.
Figure 3. Seeded fibrillation of huPrP. Different combinations of seeds from NaPTA precipitated brain homogenates of either diseased or control
animals and 3 mM huPrP as substrate within ThT amyloid seeding assay. Time dependent ThT fluorescence is shown for 3 mM huPrP in combination
with seeds from CJD-affected human brain (A), scrapie-affected sheep brain (B), BSE-affected bovine brain (C), and CWD-affected deer brain (D)
(closed circles). The controls (open rectangles) were prepared from the respective non-diseased brain material from human (A) and animals (B; C and
D).
doi:10.1371/journal.pone.0072623.g003
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Protein misfolding cyclic amplification (PMCA;[31]), was
developed originally as diagnostic tool. Prion seeds are incubated
in cellular lysate from non-infected brain tissue, containing a
plethora of cellular components. Proteinase K resistant PrP
aggregates and, in recent studies, even infectious PrPSc was
generated [32]. Even though strain characteristics of prions were
retained in these experiments, it was shown, that PMCA is capable
of overcoming naturally existing species barriers [33,34]. There-
fore, seeding activity in PMCA experiments might be too high,
due to the order of magnitudes in amplification, to be specific
enough for the analysis of the species barrier phenomenon.
Somewhat related to our approach is the QuiC method, in
which recombinant hamster PrP (90-231) is used as substrate in a
seeding assay without cellular components. Not only prions from
hamster, but also from sheep, human and mouse [35–37] could be
detected applying hamster substrate. Although the QuiC method
is very sensitive and applicable for diagnostic purposes [38], a
mechanistic characterisation of the species barrier has not been
shown, since the overcoming of naturally occurring species
barriers seems to be readily done.
In the current and our previous studies, we developed and
applied a SDS based in vitro assay, in which natural, pre-purified
PrPSc seeds and recPrP substrate are combined to form PrP fibrils
with high efficiency in absence of any additional cellular
components. Fibril formation could be quantitatively analysed in
terms of a direct molecular interaction of seed and substrate,
which is a direct consequence of the ‘‘prion-protein-only’’
hypothesis. The dependence of the lag-phase of fibril formation
on the monomer, as well as the seed concentration, is in
congruence with the mechanism of direct molecular interaction
[11,12]. After the characterisation of the homologous system,
prion seeds from different species were combined with recPrP
from hamster, mouse, sheep, cattle, deer and human as substrate.
In a preceding study, we could show, that our in vitro seeding assay
is in complete agreement with naturally occurring transmission, as
well as species barriers between the species hamster, mouse, sheep
and cattle. It was also shown, that the application of the truncated
form of recPrP as substrate has no effect on the specificity of the
seeding assay [20]. In the present work we have extended the
studies to the human and cervid species.
Transmission of CJD within humans has first been described by
cases of iatrogenic CJD (iCJD) due to dura mater transplants,
application of contaminated growth hormone or contaminated
medical instruments [39]. The transmission of variant CJD (vCJD)
via blood transfusion has been reported in recent years [40,41]. In
our studies CJD seeds and huPrP as substrate were used as an
example of intraspecies transmission and served as positive
control. As expected, we could show that CJD seeds are able to
facilitate fibrillation of huPrP.
Regarding the transmission of prions from other species to
humans, epidemiological data could show, that the occurrence of
vCJD during the BSE crisis in the late 1990s correlates with
emergence of BSE [42]. Several studies, which are based on
comparison of lesion profiles, molecular similarities and incubation
times in laboratory rodents of the two agents, show a clear
connection between BSE and vCJD [43–46]. According to these in
vivo and in vitro studies, we showed fibrillation of huPrP induced by
BSE seeds. In contrast to claims of ‘‘relatively ineffective con-
version’’ mentioned above, we show a significant seeding activity.
A case of a species barrier is described for the transmission from
sheep scrapie to humans. Analysis of epidemiological data did not
reveal any connection between the incidence of scrapie and CJD
[47–49]. Additionally, in vitro studies and studies with transgenic
mice expressing huPrPC could not show transmissibility of scrapie
to humans [18,50]. Regarding this generally accepted species
barrier, scrapie prions are not able to seed fibrillation of huPrP.
Since CWD was first described in 1981 in wildlife deer,
extensive surveillance studies were started in 1990 [51]. Today,
Figure 4. Pre-amyloid and amyloid state of cerPrP. CD spectra
(A) of cerPrP with different concentrations of SDS (0.02–0.2%) have
been recorded directly after adapting the SDS buffer conditions. CD
spectra show a shift from a-random dominated towards b-sheet rich
secondary structure with decreasing concentration of SDS. (B) De novo
fibrillation of cerPrP, an amyloid specific increase in ThT fluorescence is
observable at 0.02% SDS and 9 mM cerPrP. (C) cerPrP (3 mM) in
combination with seeds from CWD brain or control brain.
doi:10.1371/journal.pone.0072623.g004
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CWD is found in captive and free-ranging cervids in a number of
states and provinces throughout North America. The potential
transmissibility of CWD to humans is of utmost importance for
public health and is subject of current research. Some PMCA
studies showed that it is possible to seed human PrP with CWD
prions [52]. Also, non-human primates could be infected with
CWD prions [53]. In contrast, other in vitro and in vivo studies
indicate the presence of a species barrier between cervids and
humans [43,54]. In one of these studies, the conversion of human
PrPC in brain homogenate could only be shown, when CWD seeds
were pre-treated under acidic conditions, as stated ‘‘possibly by
overcoming conformational barriers in partial denaturation of
substrate’’. In neutral buffer conditions no conversion of human
PrPC could be shown. Also bioassays in transgenic mice strengthen
the assumption, that CWD is not transmissible to humans [50,55–
57]. Moreover, epidemiological studies cannot find a correlation
between CWD and human prion diseases [43,58]. Our studies do
not show any seeding activity of CWD seeds in huPrP. This
corresponds to most of the studies mentioned above, which shows
that the seeded fibrillation system presented here, faithfully
recapitulates the phenomenon of species barriers. We therefore
strongly support the hypothesis, that CWD cannot be transmitted
to humans.
In summary, our in vitro seeding results are in complete
agreement with epidemiological observations and in vivo studies.
In regard to the molecular mechanism of species barrier, we
could show, that the seeding activity and thereby solely the
molecular interaction of PrPC and prion seeds is sufficient to
explain the species barrier phenomenon in human prion diseases.
Nevertheless, it cannot be excluded, that the transmissibility
between species can be further influenced by cellular factors or
processes within the living organism. As our seeds derive only from
brain material of naturally occurring prion diseases, we have to
point out, that our conclusions may not be transferable to any
strain specific phenomena like tissue specificity or symptomless
infections [7,59].
With these restrictions in mind, our approach enables us to
investigate or even predict uncertain or unknown species barriers
by straightforward in vitro experiments compared to time
consuming and expensive bioassays in transgenic rodents.
Acknowledgments
We kindly thank our collaborators for providing us brain tissue samples:
Oliver Andreoletti, INRA ENVT (Scrapie; Medulla); Martin Groschup,
Bundesforschungsanstalt fu¨r Viruskrankheiten der Tiere (BSE, Medulla);
Neil Cashman, Canadian Cooperative Wildlife Health Centre (CWD,
white-tailed deer) and Hans Kretzschmar, Institut fu¨r Neuropathologie
und Prionforschung der LMU (sCJD)
We also thank Wolfgang Kaisers, Zentralbereich Bioinformatik,
Biologisch-Medizinisches Forschungszentrum der Heinrich Heine Uni-
versita¨t for support in statistical questions.
Finally, we thank Elke Reinartz for assistance in preparation of brain
samples and Bernd Esters for assistance in cloning and chromatography.
Author Contributions
Conceived and designed the experiments: EB LL. Performed the
experiments: LL JS MW MMW. Analyzed the data: OB EB LL LNS
DR MW. Contributed reagents/materials/analysis tools: DW. Wrote the
paper: EB LL DR DW.
References
1. Prusiner SB (2007) In: Fields BN, Knipe DM, Howley PM, Chanock RM,
Monath TP, editors. Fields Virology. Philadelphia, PA: Lippincott Williams &
Wilkins. pp. 3059–3091.
2. Ironside JW (2010) Variant Creutzfeldt-Jakob disease. Haemophilia 16 Suppl 5:
175–180.
Figure 5. Seeding activity of PrPSc seeds of different species in huPrP. The box plot shows seeding activity of seeds from the species human,
cattle, sheep and deer in huPrP obtained from identical replicates of single seeding experiments. Seeding activity was calculated by dividing the
average of relative fluorescence of samples with PrPSc positive seeds and PrPSc negative seeds within 80-100 h (plateau phase). For seeds from CJD
(N= 7) or BSE (N= 8) material a high seeding activity is observable. For seeds from scrapie (N = 10) or CWD (N=8) a strong species barrier is apparent.
doi:10.1371/journal.pone.0072623.g005
Molecular Basis of Prion Species Barrier
PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e72623
3. Cuille´ J (1936) La tremblante du mouton est bien inoculable. CR Acad Sci Paris
206: 78–79.
4. Wilesmith JW, Ryan JB, Atkinson MJ (1991) Bovine spongiform encephalop-
athy: epidemiological studies on the origin. Vet Rec 128: 199–203.
5. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, et al. (1996) A new
variant of Creutzfeldt-Jakob disease in the UK. Lancet 347: 921–925.
6. Collinge J, Clarke AR (2007) A general model of prion strains and their
pathogenicity. Science 318: 930–936.
7. Beringue V, Herzog L, Jaumain E, Reine F, Sibille P, et al. (2012) Facilitated
cross-species transmission of prions in extraneural tissue. Science 335: 472–475.
8. Riesner D (2007) The Scrapie Isoform of the Prion Protein PrPSc Compared to
the Cellular Isoform PrPC. In: Ho¨rnlimann B, Riesner D, Kretzchmar H,
editors. Prions in Humans and Animals. Berlin: De Gruyter. pp. 104–118.
9. Harper JD, Lansbury PT Jr (1997) Models of amyloid seeding in Alzheimer’s
disease and scrapie: mechanistic truths and physiological consequences of the
time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385–407.
10. Eigen M (1996) Prionics or the kinetic basis of prion diseases. Biophys Chem 63:
A1–18.
11. Stohr J, Weinmann N, Wille H, Kaimann T, Nagel-Steger L, et al. (2008)
Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci U S A
105: 2409–2414.
12. Eigen M (2001) BSE und das Prion-Problem. Spektrum der Wissenschaft: 40–
49.
13. Post K, Brown DR, Groschup M, Kretzschmar HA, Riesner D (2000)
Neurotoxicity but not infectivity of prion proteins can be induced reversibly in
vitro. Arch Virol Suppl: 265–273.
14. Leffers KW, Wille H, Stohr J, Junger E, Prusiner SB, et al. (2005) Assembly of
natural and recombinant prion protein into fibrils. Biol Chem 386: 569–580.
15. Birkmann E, Riesner D (2008) Prion infection: seeded fibrillization or more?
Prion 2: 67–72.
16. Safar J, Wille H, Itri V, Groth D, Serban H, et al. (1998) Eight prion strains have
PrP(Sc) molecules with different conformations. Nat Med 4: 1157–1165.
17. Birkmann E, Schafer O, Weinmann N, Dumpitak C, Beekes M, et al. (2006)
Detection of prion particles in samples of BSE and scrapie by fluorescence
correlation spectroscopy without proteinase K digestion. Biol Chem 387: 95–
102.
18. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, et al. (1997)
Molecular assessment of the potential transmissibilities of BSE and scrapie to
humans. Nature 388: 285–288.
19. Raymond GJ, Bossers A, Raymond LD, O’Rourke KI, McHolland LE, et al.
(2000) Evidence of a molecular barrier limiting susceptibility of humans, cattle
and sheep to chronic wasting disease. EMBO J 19: 4425–4430.
20. Panza G, Luers L, Stohr J, Nagel-Steger L, Weiss J, et al. (2010) Molecular
interactions between prions as seeds and recombinant prion proteins as
substrates resemble the biological interspecies barrier in vitro. PLoS One 5:
e14283.
21. Panza G, Stohr J, Dumpitak C, Papathanassiou D, Weiss J, et al. (2008)
Spontaneous and BSE-prion-seeded amyloid formation of full length recombi-
nant bovine prion protein. Biochem Biophys Res Commun 373: 493–497.
22. Colby DW, Zhang Q, Wang S, Groth D, Legname G, et al. (2007) Prion
detection by an amyloid seeding assay. Proc Natl Acad Sci U S A 104: 20914–
20919.
23. Durchschlag H (1986) Specific Volumes of biological macromolecules and some
other molecules of biological interest. In: Hinz H-J, editor. Thermodynamic
Data for Biochemistry and Biotechnology. Berlin: Springer Verlag. pp. 45–128.
24. Brookes E, Demeler B (2007) Parsimonious Regularization using Genetic
Algorithms Applied to the Analysis of Analytical Ultracentrifugation Experi-
ments. GECCO ACM Proceedings 978-1-59593-697-4/07/0007.
25. Brookes E, Demeler B (2010) Performance optimization of large non-negatively
constrained least squares problems with an application in biophysics.
Proceedings of the 2010 TeraGrid Conference, ACM New York, NY, USA.
26. Demeler B, Brookes E (2008) Monte Carlo analysis of sedimentation
experiments. Colloid Polym Sci 286(2): 129–137.
27. Scha¨tzl H (2007) The Phylogeny of Mammalian and Nonmammalian Prion
Proteins. In: Ho¨rnlimann B, Riesner D, Kretzchmar H, editors. Prions in
Humans and Animals. Berlin: De Gruyter. pp. 119–133.
28. Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, et al. (2004)
Synthetic mammalian prions. Science 305: 673–676.
29. Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native
prions from minimal components in vitro. Proc Natl Acad Sci U S A 104: 9741–
9746.
30. Wang F, Wang X, Yuan CG, Ma J (2010) Generating a prion with bacterially
expressed recombinant prion protein. Science 327: 1132–1135.
31. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological
prion protein by cyclic amplification of protein misfolding. Nature 411: 810–
813.
32. Castilla J, Saa P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie
prions. Cell 121: 195–206.
33. Castilla J, Gonzalez-Romero D, Saa P, Morales R, De Castro J, et al. (2008)
Crossing the species barrier by PrP(Sc) replication in vitro generates unique
infectious prions. Cell 134: 757–768.
34. Green KM, Castilla J, Seward TS, Napier DL, Jewell JE, et al. (2008)
Accelerated high fidelity prion amplification within and across prion species
barriers. PLoS Pathog 4: e1000139.
35. Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, et al. (2008)
Simplified ultrasensitive prion detection by recombinant PrP conversion with
shaking. Nat Methods 5: 211–212.
36. Orru CD, Wilham JM, Hughson AG, Raymond LD, McNally KL, et al. (2009)
Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection
using seeded conversion of recombinant prion protein. Protein Eng Des Sel 22:
515–521.
37. Vascellari S, Orru CD, Hughson AG, King D, Barron R, et al. (2012) Prion
seeding activities of mouse scrapie strains with divergent PrPSc protease
sensitivities and amyloid plaque content using RT-QuIC and eQuIC. PLoS
ONE 7: e48969.
38. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, et al. (2011) Ultrasensitive
human prion detection in cerebrospinal fluid by real-time quaking-induced
conversion. Nat Med 17: 175–178.
39. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, et al. (2012)
Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18:
901–907.
40. Andreoletti O, Litaise C, Simmons H, Corbiere F, Lugan S, et al. (2012) Highly
efficient prion transmission by blood transfusion. PLoS Pathog 8: e1002782.
41. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD
after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:
527–529.
42. Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, et al. (1998)
Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries,
1993-1995. EU Collaborative Study Group for CJD. Ann Neurol 43: 763–767.
43. Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P, et al. (2004)
Chronic wasting disease and potential transmission to humans. Emerg Infect Dis
10: 977–984.
44. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997)
Transmissions to mice indicate that ’new variant’ CJD is caused by the BSE
agent. Nature 389: 498–501.
45. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecular analysis of
prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 685–
690.
46. Scott MR, Will R, Ironside J, Nguyen HO, Tremblay P, et al. (1999) Compelling
transgenetic evidence for transmission of bovine spongiform encephalopathy
prions to humans. Proc Natl Acad Sci U S A 96: 15137–15142.
47. Johnson RT (2005) Prion diseases. Lancet Neurol 4: 635–642.
48. Caramelli M, Ru G, Acutis P, Forloni G (2006) Prion diseases: current
understanding of epidemiology and pathogenesis, and therapeutic advances.
CNS Drugs 20: 15–28.
49. Hunter N (1998) Scrapie. Mol Biotechnol 9: 225–234.
50. Wilson R, Plinston C, Hunter N, Casalone C, Corona C, et al. (2012) Chronic
wasting disease and atypical forms of bovine spongiform encephalopathy and
scrapie are not transmissible to mice expressing wild-type levels of human prion
protein. J Gen Virol 93: 1624–1629.
51. Miller MW, Conner MM (2005) Epidemiology of chronic wasting disease in
free-ranging mule deer: spatial, temporal, and demographic influences on
observed prevalence patterns. J Wildl Dis 41: 275–290.
52. Barria MA, Telling GC, Gambetti P, Mastrianni JA, Soto C (2011) Generation
of a new form of human PrP(Sc) in vitro by interspecies transmission from cervid
prions. J Biol Chem 286: 7490–7495.
53. Marsh RF, Kincaid AE, Bessen RA, Bartz JC (2005) Interspecies transmission of
chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J Virol 79:
13794–13796.
54. Li L, Coulthart MB, Balachandran A, Chakrabartty A, Cashman NR (2007)
Species barriers for chronic wasting disease by in vitro conversion of prion
protein. Biochem Biophys Res Commun 364: 796–800.
55. Sandberg MK, Al-Doujaily H, Sigurdson CJ, Glatzel M, O’Malley C, et al.
(2010) Chronic wasting disease prions are not transmissible to transgenic mice
overexpressing human prion protein. J Gen Virol 91: 2651–2657.
56. Kong Q, Huang S, Zou W, Vanegas D, Wang M, et al. (2005) Chronic wasting
disease of elk: transmissibility to humans examined by transgenic mouse models.
J Neurosci 25: 7944–7949.
57. Tamguney G, Giles K, Bouzamondo-Bernstein E, Bosque PJ, Miller MW, et al.
(2006) Transmission of elk and deer prions to transgenic mice. J Virol 80: 9104–
9114.
58. Mawhinney S, Pape WJ, Forster JE, Anderson CA, Bosque P, et al. (2006)
Human prion disease and relative risk associated with chronic wasting disease.
Emerg Infect Dis 12: 1527–1535.
59. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, et al. (2000) Species-
barrier-independent prion replication in apparently resistant species. Proc Natl
Acad Sci U S A 97: 10248–10253.
Molecular Basis of Prion Species Barrier
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e72623
